Original Literature | Model OverView |
---|---|
Publication
Title
Ubiquitin: tool and target for intracellular NF-kappaB inhibitors.
Affiliation
Unit of Molecular Signal Transduction in Inflammation, Department for MolecularBiomedical Research, Flanders Interuniversity Institute for Biotechnology (VIB)- Ghent University, Technologiepark 927, B-9052 Ghent (Zwijnaarde), Belgium.
Abstract
The transcription factor nuclear factor-kappaB (NF-kappaB) has a pivotal role ininitiating inflammation and raising an effective immune response. BecauseNF-kappaB activation depends on ubiquitination, cells have developed ubiquitin(Ub)-mediated strategies for inhibiting NF-kappaB activation and preventingexcessive inflammation. Recent findings concerning tumor necrosis factor (TNF)receptor and toll-like receptor (TLR)-interleukin-1 (IL-1) receptor signallingpathways show that Ub can be a tool as well as a target for NF-kappaB inhibitoryproteins, either by labelling specific signalling proteins forproteasome-dependent degradation or by serving as a target for specificde-ubiquitinating enzymes that prevent the formation of pertinent signallingcomplexes. Interfering with ubiquitination therefore seems to be a versatilemeans for regulating NF-kappaB activity, indicating that studies of Ub-mediatedsignalling might hold the key for developing new therapeutic strategies forinflammatory disease.
PMID
16982211
|
Entity
Process
TRAF2
--
MO000000209
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m180
10
infinite
0
InterPro | IPR001841 |
TRANSPATH | MO000000209 |
--
TRAF6
--
MO000000212
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m183
10
infinite
0
InterPro | IPR001841 |
TRANSPATH | MO000000212 |
--
IRAK-1
--
MO000000213
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m184
10
infinite
0
InterPro | IPR000719 |
TRANSPATH | MO000000213 |
--
IkappaB-alpha
--
MO000000233
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m199
10
infinite
0
InterPro | IPR002110 |
TRANSPATH | MO000000233 |
--
p50:RelA-p65:IkappaB-alpha{p}
--
MO000000254
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m208
10
infinite
0
TRANSPATH | MO000000254 |
--
A20
--
MO000016591
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m1585
10
infinite
0
InterPro | IPR002653 |
TRANSPATH | MO000016591 |
--
p50:RelA-p65 {activated}
--
MO000016632
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m1617
10
infinite
0
TRANSPATH | MO000016632 |
--
IKK-alpha:IKK-beta:(IKK-gamma)2
--
MO000016661
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m1637
10
infinite
0
TRANSPATH | MO000016661 |
--
TNFR2
--
MO000016921
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m1836
10
infinite
0
InterPro | IPR001368 |
TRANSPATH | MO000016921 |
--
SOCS-1
--
MO000017004
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m1906
10
infinite
0
InterPro | IPR001496 |
TRANSPATH | MO000017004 |
--
protein remnants
--
MO000019479
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m360980
10
infinite
0
TRANSPATH | MO000019479 |
--
Siah-2
--
MO000021586
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m5930
10
infinite
0
InterPro | IPR001841 |
TRANSPATH | MO000021586 |
--
p50:RelA-p65:IkappaB-alpha
--
MO000038724
cso30:c:Complex
cso30:i:CC_CellComponent
--
csml-variable:Double
m16910
10
infinite
0
TRANSPATH | MO000038724 |
--
IRAK-4
--
MO000039077
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m17258
10
infinite
0
TRANSPATH | MO000039077 |
--
IL-1beta:IL-1RI:IL-1RAcP:MyD88
--
MO000039096
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m17272
10
infinite
0
TRANSPATH | MO000039096 |
--
CYLD
--
MO000041169
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m19042
10
infinite
0
TRANSPATH | MO000041169 |
--
--
e1
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane
--
--
--
csml-variable:Double
m1
0
infinite
0
--
--
e10
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cytosol
--
--
--
csml-variable:Double
m10
0
infinite
0
--
--
e100
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
--
csml-variable:Double
m100
0
infinite
0
--
--
e101
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane_ExternalSideOfPlasmaMembrane_
--
--
--
csml-variable:Double
m101
0
infinite
0
--
--
e102
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cell
--
--
--
csml-variable:Double
m102
0
infinite
0
--
--
e103
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cytosol
--
--
--
csml-variable:Double
m103
0
infinite
0
--
--
e104
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cell_WithoutCellWall_
--
--
--
csml-variable:Double
m104
0
infinite
0
--
--
e105
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cytoplasm
--
--
--
csml-variable:Double
m105
0
infinite
0
--
TNF-alpha: TNFR2
--
e106
cso30:c:Complex
cso30:i:CC_Extracellular
--
--
csml-variable:Double
m106
0
infinite
0
--
TNF-alpha: TNFR: TRADD
--
e11
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m12
0
infinite
0
--
TNF-alpha: TNFR: TRADD: TRAF2: RIP
--
e12
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m13
0
infinite
0
--
TNF-alpha: TNFR: TRADD: TRAF2 {ubK63}n: RIP
--
e13
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m14
0
infinite
0
--
TRAF2 {ub}n: RIP {ubK63}n
--
e14
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m15
0
infinite
0
--
TRAF2 {ubK63}n: RIP
--
e15
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m16
0
infinite
0
--
TRAF2 {ub}n: RIP {ubK63}n: TAB2: TAB3: IKK-alpha:IKK-beta:(IKK-gamma)2
--
e16
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m17
0
infinite
0
--
TRAF2 {ub}n: RIP {ubK63}n: TAB2: TAB3: IKK-alpha {p}:IKK-beta {p}:(IKK-gamma)2 : TAK1
--
e17
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m18
0
infinite
0
--
IL-1RI: IL-RAcP
--
e18
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m19
0
infinite
0
--
TRAF2 {ub}n: RIP {ubK63}n: TAB2: TAB3: IKK-alpha:IKK-beta:(IKK-gamma)2: TAK1
--
e19
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m20
0
infinite
0
--
--
e2
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane_ExternalSideOfPlasmaMembrane_
--
--
--
csml-variable:Double
m2
0
infinite
0
--
IL-1beta: IL-1RI: IL-RAcP
--
e20
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_ExternalSideOfPlasmaMembrane_
--
csml-variable:Double
m21
0
infinite
0
--
TLR4: MD-2: CD14
--
e21
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m22
0
infinite
0
--
LPS: TLR4: MD-2: CD14
--
e22
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m23
0
infinite
0
--
LPS: TLR4: MD-2: CD14: MyD88
--
e23
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m24
0
infinite
0
--
LPS: TLR4: MD-2: CD14: MAL
--
e24
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m25
0
infinite
0
--
LPS: TLR4: MD-2: CD14: MyD88: IRAK-1: IRAK-4
--
e25
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m26
0
infinite
0
--
LPS: TLR4: MD-2: CD14: MyD88: IRAK-1: IRAK-4: TRAF6
--
e26
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m27
0
infinite
0
--
IL-1beta:IL-1RI:IL-1RAcP:MyD88: IRAK-1: IRAK-4
--
e27
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m28
0
infinite
0
--
IL-1beta:IL-1RI:IL-1RAcP:MyD88: IRAK-1: IRAK-4: TRAF6
--
e28
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_ExternalSideOfPlasmaMembrane_
--
csml-variable:Double
m29
0
infinite
0
--
IL-1beta:IL-1RI:IL-1RAcP:MyD88: IRAK-1{p}: IRAK-4: TRAF6
--
e29
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_ExternalSideOfPlasmaMembrane_
--
csml-variable:Double
m30
0
infinite
0
--
--
e3
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
--
csml-variable:Double
m3
0
infinite
0
--
LPS: TLR4: MD-2: CD14: MyD88: IRAK-1{p}: IRAK-4: TRAF6
--
e30
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m31
0
infinite
0
--
IL-1beta:IL-1RI:IL-1RAcP:MyD88: IRAK-4
--
e31
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m32
0
infinite
0
--
LPS: TLR4: MD-2: CD14: MyD88: IRAK-4
--
e32
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m33
0
infinite
0
--
IRAK-1 {p}: TRAF6 {ubK63}n
--
e33
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m34
0
infinite
0
--
IRAK-1 {p}: TRAF6
--
e34
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m35
0
infinite
0
--
TAK1: TAB2: TAB3
--
e35
cso30:c:Complex
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m36
0
infinite
0
--
IRAK-1 {p}: TRAF6 {ubK63}n: TAK1: TAb2: TAb3
--
e36
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m37
0
infinite
0
--
IKK-alpha {p}:IKK-beta {p}:(IKK-gamma)2
--
e37
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m38
0
infinite
0
--
p50:RelA-p65:IkappaB-alpha{p} {ubK48}
--
e38
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m39
0
infinite
0
--
p50:RelA-p65 {nucleus}
--
e39
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m5
10
infinite
0
TRANSPATH | MO000016632 |
--
--
e4
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane_InternalSideOfPlasmaMembrane_
--
--
--
csml-variable:Double
m4
0
infinite
0
--
NF-kappaB responsive genes: p50:RelA-p65
--
e40
cso30:c:Complex
cso30:i:CC_Nucleoplasm
--
csml-variable:Double
m40
0
infinite
0
--
NF-kappaB responsive genes
--
e41
cso30:c:Dna
cso30:i:CC_Nucleoplasm
--
csml-variable:Double
m41
0
infinite
0
--
IkappaB-alpha (cytoplasmic)
--
e42
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m42
10
infinite
0
InterPro | IPR002110 |
TRANSPATH | MO000000233 |
--
p50:RelA-p65:IkappaB-alpha {nucleus}
--
e43
cso30:c:Complex
cso30:i:CC_Nucleoplasm
--
csml-variable:Double
m43
0
infinite
0
--
IL-8
--
e44
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
csml-variable:Double
m44
0
infinite
0
--
Eotaxin
--
e45
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
csml-variable:Double
m45
0
infinite
0
--
Eotaxin
--
e46
cso30:c:Protein
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m46
0
infinite
0
--
TRAF2 {ub}n: RIP {ubK63}n: TAB2: TAB3: IKK-alpha {p}:IKK-beta {p}:(IKK-gamma)2 {ub}: TAK1
--
e47
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m47
0
infinite
0
--
OTUD7B
--
e48
cso30:c:Protein
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m48
0
infinite
0
--
TRAF6: OTUD7B
--
e49
cso30:c:Complex
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m49
0
infinite
0
--
--
e50
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearEnvelopeLumen
--
--
--
csml-variable:Double
m50
0
infinite
0
--
--
e51
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearPore
--
--
--
csml-variable:Double
m51
0
infinite
0
--
--
e52
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearInnerMembrane
--
--
--
csml-variable:Double
m52
0
infinite
0
--
--
e53
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearLumen
--
--
--
csml-variable:Double
m53
0
infinite
0
--
--
e54
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearOuterMembrane
--
--
--
csml-variable:Double
m54
0
infinite
0
--
--
e55
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Nucleus
--
--
--
csml-variable:Double
m55
0
infinite
0
--
--
e56
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Nucleoplasm
--
--
--
csml-variable:Double
m56
0
infinite
0
--
--
e57
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearBody
--
--
--
csml-variable:Double
m57
0
infinite
0
--
--
e58
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Nucleolus
--
--
--
csml-variable:Double
m58
0
infinite
0
--
--
e59
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearEnvelope
--
--
--
csml-variable:Double
m59
0
infinite
0
--
TNF-alpha: TNFR
--
e6
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m11
0
infinite
0
--
--
e60
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Chromatin
--
--
--
csml-variable:Double
m60
0
infinite
0
--
--
e61
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearChromosome
--
--
--
csml-variable:Double
m61
0
infinite
0
--
--
e62
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearCentromere
--
--
--
csml-variable:Double
m62
0
infinite
0
--
Bcl-3 {ub}
--
e63
cso30:c:Protein
cso30:i:CC_Cytosol
--
csml-variable:Double
m63
0
infinite
0
--
Bcl-3 {ub}{nucleus}
--
e64
cso30:c:Protein
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m64
0
infinite
0
--
TRAF2: USP31
--
e65
cso30:c:Complex
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m65
0
infinite
0
--
TLR4: TRIAD3A
--
e66
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m66
0
infinite
0
--
TLR9: TRIAD3A
--
e67
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m67
0
infinite
0
--
TLR9 {ub}n: TRIAD3A
--
e69
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m69
0
infinite
0
--
--
e7
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cell
--
--
--
csml-variable:Double
m7
0
infinite
0
--
TLR4 {ub}n: TRIAD3A
--
e70
cso30:c:Complex
cso30:i:CC_Extracellular
--
csml-variable:Double
m70
0
infinite
0
--
ASB3
--
e71
cso30:c:Protein
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m71
0
infinite
0
--
csml-variable:Double
m72
0
infinite
0
--
TNFR2 {ubK48}n
--
e73
cso30:c:Protein
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m73
0
infinite
0
--
ASB3: elongin B: elongin C: cullin-2: Rbx2: E2
--
e74
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m74
0
infinite
0
--
TNF: TNFR2
--
e75
cso30:c:Complex
cso30:i:CC_Extracellular
--
csml-variable:Double
m75
0
infinite
0
--
TNF: TNFR2: TRAF2
--
e76
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m76
0
infinite
0
--
TNF-alpha: TNFR2: TRAF2 {ub}: BIRC2
--
e78
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m78
0
infinite
0
--
TNF: TNFR2: TRAF2: BIRC2
--
e79
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m79
0
infinite
0
--
--
e8
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cell_WithoutCellWall_
--
--
--
csml-variable:Double
m8
0
infinite
0
--
--
e80
cso30:c:EntityBiologicalCompartment
cso30:i:CC_EndoplasmicReticulum_IntegralToMembrane_
--
--
--
csml-variable:Double
m80
0
infinite
0
--
--
e81
cso30:c:EntityBiologicalCompartment
cso30:i:CC_EndoplasmicReticulum_Membrane_
--
--
--
csml-variable:Double
m81
0
infinite
0
--
--
e82
cso30:c:EntityBiologicalCompartment
cso30:i:CC_EndoplasmicReticulumLumen
--
--
--
csml-variable:Double
m82
0
infinite
0
--
--
e83
cso30:c:EntityBiologicalCompartment
cso30:i:CC_EndoplasmicReticulum
--
--
--
csml-variable:Double
m83
0
infinite
0
--
--
e84
cso30:c:EntityBiologicalCompartment
cso30:i:CC_EndoplasmicReticulum_ExtrinsicToInternalSideOfMembrane_
--
--
--
csml-variable:Double
m84
0
infinite
0
--
--
e85
cso30:c:EntityBiologicalCompartment
cso30:i:CC_EndoplasmicReticulum_ExtrinsicToExternalSideOfMembrane_
--
--
--
csml-variable:Double
m85
0
infinite
0
--
TNF-alpha: TNFR2: TRAF2: BIRC2
--
e86
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m86
0
infinite
0
--
csml-variable:Double
m87
0
infinite
0
--
csml-variable:Double
m88
10
infinite
0
Affymetrix | 1553717_at |
Ensembl | ENSG00000154710 |
HGNC | KCTD7 |
OMIM | 609700 |
Proteome | HumanPSD/RABGEF1 |
RefSeq | NM_014504 |
TRANSFAC | G007098 |
Unigene | Hs.103838 |
--
csml-variable:Double
m89
10
infinite
0
Affymetrix | 1422031_a_at |
Ensembl | ENSMUSG00000030629 |
MGD | 3110005P07Rik |
Proteome | HumanPSD/Zfand6 |
RefSeq | NM_022985 |
TRANSFAC | G045281 |
Unigene | Mm.1608 |
--
--
e9
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cytoplasm
--
--
--
csml-variable:Double
m9
0
infinite
0
--
OTUD7B
--
e90
cso30:c:mRNA
cso30:i:CC_Cytosol
--
csml-variable:Double
m90
0
infinite
0
--
Zfand5
--
e91
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
csml-variable:Double
m91
0
infinite
0
--
LPS: TLR4: MD-2: CD14: MAL {ub}
--
e92
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m92
0
infinite
0
--
LPS: TLR4: MD-2: CD14: MAL {p}
--
e93
cso30:c:Complex
cso30:i:CC_Extracellular
--
csml-variable:Double
m93
0
infinite
0
--
p50: RelA-p65 {ub}n
--
e94
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m94
0
infinite
0
--
IRAK1: SOCS-1
--
e95
cso30:c:Complex
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m95
0
infinite
0
--
TRAF6: TAK1: SOCS-1
--
e96
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m96
0
infinite
0
--
IRAK-1 {p}: TRAF6 {ubK63}n: TAK1 {activated}: TAb2: TAb3
--
e97
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m97
0
infinite
0
--
--
e98
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane_InternalSideOfPlasmaMembrane_
--
--
--
csml-variable:Double
m98
0
infinite
0
--
--
e99
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane
--
--
--
csml-variable:Double
m99
0
infinite
0
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c1 : 1
stoichiometry:c2 : 1
stoichiometry:c3 : 1
m6*m176*0.1
nodelay
--
0
PMID: 16982211 The binding of TNF to TNF receptor-1 (TNF-R1; the main receptor for soluble TNF on most cell types) (A) leads to the recruitment of TNF receptor-1 associated death domain protein (TRADD; red), which in turn recruits TNF receptor-associated factor 2 (TRAF2; orange) and receptor-interacting protein (RIP; dark grey).
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c28 : 1
stoichiometry:c29 : 1
stoichiometry:c30 : 1
m1591*m19*0.1
nodelay
--
0
PMID: 16982211 The binding of IL-1beta to the IL-1 receptor (IL-1R)?IL-1R accessory protein (IL-1RAcP) complex (B), or the binding of lipopolysaccharide (LPS) to the TLR4?MD2?CD14 complex (C), leads to the recruitment of myeloid differentiation factor 88 (MyD88; light yellow) and MyD88 adaptor-like (MAL), which subsequently recruit IL-1 receptor-associated kinase 1 (IRAK1; green), IRAK4 (purple) and TRAF6 (dark blue) to the receptor complex.
p11
p11
cso30:i:ME_Binding
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c31 : 1
stoichiometry:c33 : 1
stoichiometry:c32 : 1
m21*m1572*0.1
nodelay
--
0
PMID: 16982211 The binding of IL-1beta to the IL-1 receptor (IL-1R)?IL-1R accessory protein (IL-1RAcP) complex (B), or the binding of lipopolysaccharide (LPS) to the TLR4?MD2?CD14 complex (C), leads to the recruitment of myeloid differentiation factor 88 (MyD88; light yellow) and MyD88 adaptor-like (MAL), which subsequently recruit IL-1 receptor-associated kinase 1 (IRAK1; green), IRAK4 (purple) and TRAF6 (dark blue) to the receptor complex.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c34 : 1
stoichiometry:c35 : 1
stoichiometry:c36 : 1
m157177*m22*0.1
nodelay
--
0
PMID: 16982211 The binding of IL-1beta to the IL-1 receptor (IL-1R)?IL-1R accessory protein (IL-1RAcP) complex (B), or the binding of lipopolysaccharide (LPS) to the TLR4?MD2?CD14 complex (C), leads to the recruitment of myeloid differentiation factor 88 (MyD88; light yellow) and MyD88 adaptor-like (MAL), which subsequently recruit IL-1 receptor-associated kinase 1 (IRAK1; green), IRAK4 (purple) and TRAF6 (dark blue) to the receptor complex.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c42 : 1
stoichiometry:c37 : 1
stoichiometry:c39 : 1
m25*m1572*0.1
nodelay
--
0
PMID: 16982211 The binding of IL-1beta to the IL-1 receptor (IL-1R)?IL-1R accessory protein (IL-1RAcP) complex (B), or the binding of lipopolysaccharide (LPS) to the TLR4?MD2?CD14 complex (C), leads to the recruitment of myeloid differentiation factor 88 (MyD88; light yellow) and MyD88 adaptor-like (MAL), which subsequently recruit IL-1 receptor-associated kinase 1 (IRAK1; green), IRAK4 (purple) and TRAF6 (dark blue) to the receptor complex.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c40 : 1
stoichiometry:c60 : 1
stoichiometry:c41 : 1
m43675*m23*0.1
nodelay
--
0
PMID: 16982211 The binding of IL-1beta to the IL-1 receptor (IL-1R)?IL-1R accessory protein (IL-1RAcP) complex (B), or the binding of lipopolysaccharide (LPS) to the TLR4?MD2?CD14 complex (C), leads to the recruitment of myeloid differentiation factor 88 (MyD88; light yellow) and MyD88 adaptor-like (MAL), which subsequently recruit IL-1 receptor-associated kinase 1 (IRAK1; green), IRAK4 (purple) and TRAF6 (dark blue) to the receptor complex.
p15
p15
cso30:i:ME_Binding
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c38 : 1
stoichiometry:c43 : 1
stoichiometry:c44 : 1
stoichiometry:c45 : 1
m184*m17258*m24*0.1
nodelay
--
0
PMID: 16982211 The binding of IL-1beta to the IL-1 receptor (IL-1R)?IL-1R accessory protein (IL-1RAcP) complex (B), or the binding of lipopolysaccharide (LPS) to the TLR4?MD2?CD14 complex (C), leads to the recruitment of myeloid differentiation factor 88 (MyD88; light yellow) and MyD88 adaptor-like (MAL), which subsequently recruit IL-1 receptor-associated kinase 1 (IRAK1; green), IRAK4 (purple) and TRAF6 (dark blue) to the receptor complex.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c46 : 1
stoichiometry:c48 : 1
stoichiometry:c47 : 1
m183*m26*0.1
nodelay
--
0
PMID: 16982211 The binding of IL-1beta to the IL-1 receptor (IL-1R)?IL-1R accessory protein (IL-1RAcP) complex (B), or the binding of lipopolysaccharide (LPS) to the TLR4?MD2?CD14 complex (C), leads to the recruitment of myeloid differentiation factor 88 (MyD88; light yellow) and MyD88 adaptor-like (MAL), which subsequently recruit IL-1 receptor-associated kinase 1 (IRAK1; green), IRAK4 (purple) and TRAF6 (dark blue) to the receptor complex.
p17
p17
cso30:i:ME_Binding
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c49 : 1
stoichiometry:c50 : 1
stoichiometry:c258 : 1
stoichiometry:c52 : 1
m17258*m184*m17272*0.1
nodelay
--
0
PMID: 16982211 The binding of IL-1beta to the IL-1 receptor (IL-1R)?IL-1R accessory protein (IL-1RAcP) complex (B), or the binding of lipopolysaccharide (LPS) to the TLR4?MD2?CD14 complex (C), leads to the recruitment of myeloid differentiation factor 88 (MyD88; light yellow) and MyD88 adaptor-like (MAL), which subsequently recruit IL-1 receptor-associated kinase 1 (IRAK1; green), IRAK4 (purple) and TRAF6 (dark blue) to the receptor complex.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c53 : 1
stoichiometry:c54 : 1
stoichiometry:c55 : 1
m28*m183*0.1
nodelay
--
0
PMID: 16982211 The binding of IL-1beta to the IL-1 receptor (IL-1R)?IL-1R accessory protein (IL-1RAcP) complex (B), or the binding of lipopolysaccharide (LPS) to the TLR4?MD2?CD14 complex (C), leads to the recruitment of myeloid differentiation factor 88 (MyD88; light yellow) and MyD88 adaptor-like (MAL), which subsequently recruit IL-1 receptor-associated kinase 1 (IRAK1; green), IRAK4 (purple) and TRAF6 (dark blue) to the receptor complex.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c56 : 1
stoichiometry:c57 : 1
m29*0.1
nodelay
--
0
PMID: 16982211 The phosphorylation of IRAK1 by IRAK4 (B1, C1) leads to the hyperphosphorylation of IRAK1 (B2, C2), followed by the dissociation of the IRAK1?TRAF6 complex from the receptor.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c4 : 1
stoichiometry:c6 : 1
stoichiometry:c5 : 1
m11*m178*0.1
nodelay
--
0
PMID: 16982211 The binding of TNF to TNF receptor-1 (TNF-R1; the main receptor for soluble TNF on most cell types) (A) leads to the recruitment of TNF receptor-1 associated death domain protein (TRADD; red), which in turn recruits TNF receptor-associated factor 2 (TRAF2; orange) and receptor-interacting protein (RIP; dark grey).
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c58 : 1
stoichiometry:c59 : 1
m27*0.1
nodelay
--
0
PMID: 16982211 The phosphorylation of IRAK1 by IRAK4 (B1, C1) leads to the hyperphosphorylation of IRAK1 (B2, C2), followed by the dissociation of the IRAK1?TRAF6 complex from the receptor.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c64 : 1
stoichiometry:c65 : 1
stoichiometry:c66 : 1
m31*0.1
nodelay
--
0
PMID: 16982211 The phosphorylation of IRAK1 by IRAK4 (B1, C1) leads to the hyperphosphorylation of IRAK1 (B2, C2), followed by the dissociation of the IRAK1?TRAF6 complex from the receptor.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c61 : 1
stoichiometry:c62 : 1
stoichiometry:c63 : 1
m30*0.1
nodelay
--
0
PMID: 16982211 The phosphorylation of IRAK1 by IRAK4 (B1, C1) leads to the hyperphosphorylation of IRAK1 (B2, C2), followed by the dissociation of the IRAK1?TRAF6 complex from the receptor.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c67 : 1
stoichiometry:c252 : 1
stoichiometry:c68 : 1
m35*0.1
nodelay
--
0
PMID: 16982211 Once released from the receptor, the Ub-ligase activity of TRAF6 mediates its K63 auto-polyubiquitination (BC3). PMID: 16982211, 16543409 This is further supported by the finding that overexpression of SOCS3 inhibits IL-1-induced NF-kappaB activation and co-immunoprecipitates with the TRAF6?TAK1 complex.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c69 : 1
stoichiometry:c70 : 1
stoichiometry:c71 : 1
m36*m34*0.1
nodelay
--
0
PMID: 16982211 K63-polyubiquitinated TRAF6 then recruits the TAK1?TAB2?TAB3 complex, which subsequently phosphorylates and activates IKKalpha and IKKbeta (BC4).
p25
p25
cso30:i:ME_Phosphorylation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c72 : 1
stoichiometry:c74 : 1
stoichiometry:c255 : 1
stoichiometry:c73 : 1
m1637*m37*m97*0.1
nodelay
--
0
PMID: 16982211 K63-polyubiquitinated TRAF6 then recruits the TAK1?TAB2?TAB3 complex, which subsequently phosphorylates and activates IKKalpha and IKKbeta (BC4).
p26
p26
cso30:i:ME_Phosphorylation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c75 : 1
stoichiometry:c77 : 1
stoichiometry:c76 : 1
m16910*m38*0.1
nodelay
--
0
PMID: 16982211 The IKKbeta catalytic subunit then phosphorylates the inhibitor of kappaB (IkappaB)¦Á protein (D1), which keeps NF-kappaB (shown here as a p65?p50 dimer) in the cytoplasm of resting cells.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c78 : 1
stoichiometry:c79 : 1
m208*0.1
nodelay
--
0
PMID: 16982211 IkappaBalpha phosphorylation leads to its K48 polyubiquitination (D2) and subsequent proteasomal degradation (D3).
p28
p28
cso30:i:ME_ProteasomeDegradation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c80 : 1
stoichiometry:c171 : 1
stoichiometry:c221 : 1
stoichiometry:c222 : 1
stoichiometry:c223 : 1
stoichiometry:c224 : 1
stoichiometry:c225 : 1
stoichiometry:c257 : 1
stoichiometry:c82 : 1
stoichiometry:c81 : 1
m39*0.1
nodelay
--
0
PMID: 16982211 IkappaBalpha phosphorylation leads to its K48 polyubiquitination (D2) and subsequent proteasomal degradation (D3). PMID: 16982211, 16214042 Recently, ubiquitin specific peptidase 31 (USP31) was identified as another TRAF2 binding DUB that inhibits TNF-induced NF-kappaB activation upon overexpression. PMID: 16982211, 8557994, 11463333, 16204640 Interestingly, overexpression of these genes was shown to inhibit TNF-induced and IL-1-induced NF-kappaB activation. PMID: 16982211, 16543409 This is further supported by the finding that overexpression of SOCS3 inhibits IL-1-induced NF-kappaB activation and co-immunoprecipitates with the TRAF6?TAK1 complex.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c83 : 1
stoichiometry:c84 : 1
m1617*0.1
nodelay
--
0
PMID: 16982211 This allows NF-kappaB to translocate to the nucleus (D4), where it induces the transcription of genes with an NF-kappaB consensus site in their promoter region, including IkappaBalpha.
p3
p3
cso30:i:ME_Binding
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c7 : 1
stoichiometry:c8 : 1
stoichiometry:c9 : 1
stoichiometry:c10 : 1
m12*m180*m179*0.1
nodelay
--
0
PMID: 16982211 The binding of TNF to TNF receptor-1 (TNF-R1; the main receptor for soluble TNF on most cell types) (A) leads to the recruitment of TNF receptor-1 associated death domain protein (TRADD; red), which in turn recruits TNF receptor-associated factor 2 (TRAF2; orange) and receptor-interacting protein (RIP; dark grey).
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c90 : 1
stoichiometry:c91 : 1
m40*0.1
nodelay
--
0
PMID: 16982211 This allows NF-kappaB to translocate to the nucleus (D4), where it induces the transcription of genes with an NF-kappaB consensus site in their promoter region, including IkappaBalpha.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c85 : 1
stoichiometry:c86 : 1
stoichiometry:c87 : 1
m5*m41*0.1
nodelay
--
0
PMID: 16982211 This allows NF-kappaB to translocate to the nucleus (D4), where it induces the transcription of genes with an NF-kappaB consensus site in their promoter region, including IkappaBalpha.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c89 : 1
stoichiometry:c102 : 1
stoichiometry:c96 : 1
m199*m5*0.1
nodelay
--
0
PMID: 16982211 This newly synthesized I¦ÊB¦Á can establish a negative-feedback loop by moving to the nucleus (D5), where it removes DNA-bound NF-kappaB complexes from their cognate sites and exports them back to the cytoplasm (D6).
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c93 : 1
stoichiometry:c92 : 1
m93713*0.1
nodelay
--
0
PMID: 16982211 This newly synthesized I¦ÊB¦Á can establish a negative-feedback loop by moving to the nucleus (D5), where it removes DNA-bound NF-kappaB complexes from their cognate sites and exports them back to the cytoplasm (D6).
p34
p34
cso30:i:ME_Translocation
cso30:i:CC_NuclearOuterMembrane
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c94 : 1
stoichiometry:c95 : 1
m42*0.1
nodelay
--
0
PMID: 16982211 This newly synthesized I¦ÊB¦Á can establish a negative-feedback loop by moving to the nucleus (D5), where it removes DNA-bound NF-kappaB complexes from their cognate sites and exports them back to the cytoplasm (D6).
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c97 : 1
stoichiometry:c98 : 1
m43*0.1
nodelay
--
0
PMID: 16982211 This newly synthesized I¦ÊB¦Á can establish a negative-feedback loop by moving to the nucleus (D5), where it removes DNA-bound NF-kappaB complexes from their cognate sites and exports them back to the cytoplasm (D6).
p36
p36
cso30:i:ME_Dissociation
cso30:i:CC_Nucleoplasm
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c88 : 1
stoichiometry:c101 : 1
stoichiometry:c99 : 1
stoichiometry:c100 : 1
m40*m199*0.1
nodelay
--
0
PMID: 16982211 This newly synthesized I¦ÊB¦Á can establish a negative-feedback loop by moving to the nucleus (D5), where it removes DNA-bound NF-kappaB complexes from their cognate sites and exports them back to the cytoplasm (D6).
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c103 : 1
stoichiometry:c104 : 1
m40*0.1
nodelay
--
0
PMID: 16982211 TLR-induced activation of NF-kappaB leads to the expression of several NF-kappaB-dependent genes, including cytokines such as tumor necrosis factor (TNF) and interleukin (IL)-1beta, both of which also directly activate the NF-kappaB pathway and thus establish a positive autoregulatory loop.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c11 : 1
stoichiometry:c12 : 1
m13*0.1
nodelay
--
0
PMID: 16982211 After its Ub ligase activity is turned on, TRAF2 catalyses K63 polyubiquitination of itself (A1).
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c107 : 1
stoichiometry:c108 : 1
m40*0.1
nodelay
--
0
PMID: 16982211 TLR-induced activation of NF-kappaB leads to the expression of several NF-kappaB-dependent genes, including cytokines such as tumor necrosis factor (TNF) and interleukin (IL)-1beta, both of which also directly activate the NF-kappaB pathway and thus establish a positive autoregulatory loop.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c112 : 1
stoichiometry:c113 : 1
m40*0.1
nodelay
--
0
PMID: 16982211, 12360211 This simultaneous and well-orchestrated activation of NF-kappaB by PAMPs and pro-inflammatory cytokines leads to the production of NF-kappaB-dependent chemokines (e.g. IL-8 and eotaxin), adhesion molecules (e.g. E-selectin and intercellular adhesion molecule 1) and inducible enzymes (e.g. inducible nitric oxide synthase and cyclo-oxygenase-2), all of which contribute to the strength and duration of the inflammatory response.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c111 : 1
stoichiometry:c114 : 1
m44*0.1
nodelay
--
0
PMID: 16982211, 12360211 This simultaneous and well-orchestrated activation of NF-kappaB by PAMPs and pro-inflammatory cytokines leads to the production of NF-kappaB-dependent chemokines (e.g. IL-8 and eotaxin), adhesion molecules (e.g. E-selectin and intercellular adhesion molecule 1) and inducible enzymes (e.g. inducible nitric oxide synthase and cyclo-oxygenase-2), all of which contribute to the strength and duration of the inflammatory response.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c115 : 1
stoichiometry:c116 : 1
m45*0.1
nodelay
--
0
PMID: 16982211, 12360211 This simultaneous and well-orchestrated activation of NF-kappaB by PAMPs and pro-inflammatory cytokines leads to the production of NF-kappaB-dependent chemokines (e.g. IL-8 and eotaxin), adhesion molecules (e.g. E-selectin and intercellular adhesion molecule 1) and inducible enzymes (e.g. inducible nitric oxide synthase and cyclo-oxygenase-2), all of which contribute to the strength and duration of the inflammatory response.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c117 : 1
stoichiometry:c118 : 1
m40*0.1
nodelay
--
0
PMID: 16982211, 12360211 This simultaneous and well-orchestrated activation of NF-kappaB by PAMPs and pro-inflammatory cytokines leads to the production of NF-kappaB-dependent chemokines (e.g. IL-8 and eotaxin), adhesion molecules (e.g. E-selectin and intercellular adhesion molecule 1) and inducible enzymes (e.g. inducible nitric oxide synthase and cyclo-oxygenase-2), all of which contribute to the strength and duration of the inflammatory response.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c119 : 1
stoichiometry:c120 : 1
m40*0.1
nodelay
--
0
PMID: 16982211, 12360211 This simultaneous and well-orchestrated activation of NF-kappaB by PAMPs and pro-inflammatory cytokines leads to the production of NF-kappaB-dependent chemokines (e.g. IL-8 and eotaxin), adhesion molecules (e.g. E-selectin and intercellular adhesion molecule 1) and inducible enzymes (e.g. inducible nitric oxide synthase and cyclo-oxygenase-2), all of which contribute to the strength and duration of the inflammatory response.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c122 : 1
stoichiometry:c121 : 1
m93313*0.1
nodelay
--
0
PMID: 16982211, 12360211 This simultaneous and well-orchestrated activation of NF-kappaB by PAMPs and pro-inflammatory cytokines leads to the production of NF-kappaB-dependent chemokines (e.g. IL-8 and eotaxin), adhesion molecules (e.g. E-selectin and intercellular adhesion molecule 1) and inducible enzymes (e.g. inducible nitric oxide synthase and cyclo-oxygenase-2), all of which contribute to the strength and duration of the inflammatory response.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c126 : 1
stoichiometry:c125 : 1
m93403*0.1
nodelay
--
0
PMID: 16982211, 12360211 This simultaneous and well-orchestrated activation of NF-kappaB by PAMPs and pro-inflammatory cytokines leads to the production of NF-kappaB-dependent chemokines (e.g. IL-8 and eotaxin), adhesion molecules (e.g. E-selectin and intercellular adhesion molecule 1) and inducible enzymes (e.g. inducible nitric oxide synthase and cyclo-oxygenase-2), all of which contribute to the strength and duration of the inflammatory response.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c123 : 1
stoichiometry:c124 : 1
m40*0.1
nodelay
--
0
PMID: 16982211, 12360211 This simultaneous and well-orchestrated activation of NF-kappaB by PAMPs and pro-inflammatory cytokines leads to the production of NF-kappaB-dependent chemokines (e.g. IL-8 and eotaxin), adhesion molecules (e.g. E-selectin and intercellular adhesion molecule 1) and inducible enzymes (e.g. inducible nitric oxide synthase and cyclo-oxygenase-2), all of which contribute to the strength and duration of the inflammatory response.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c127 : 1
stoichiometry:c128 : 1
m40*0.1
nodelay
--
0
PMID: 16982211, 12360211 This simultaneous and well-orchestrated activation of NF-kappaB by PAMPs and pro-inflammatory cytokines leads to the production of NF-kappaB-dependent chemokines (e.g. IL-8 and eotaxin), adhesion molecules (e.g. E-selectin and intercellular adhesion molecule 1) and inducible enzymes (e.g. inducible nitric oxide synthase and cyclo-oxygenase-2), all of which contribute to the strength and duration of the inflammatory response.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c13 : 1
stoichiometry:c15 : 1
stoichiometry:c14 : 1
m14*0.1
nodelay
--
0
PMID: 16982211 This causes the release of TRAF2 into the cytosol and TRAF2-mediated K63 polyubiqutination of RIP (A2).
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c130 : 1
stoichiometry:c129 : 1
m93479*0.1
nodelay
--
0
PMID: 16982211, 12360211 This simultaneous and well-orchestrated activation of NF-kappaB by PAMPs and pro-inflammatory cytokines leads to the production of NF-kappaB-dependent chemokines (e.g. IL-8 and eotaxin), adhesion molecules (e.g. E-selectin and intercellular adhesion molecule 1) and inducible enzymes (e.g. inducible nitric oxide synthase and cyclo-oxygenase-2), all of which contribute to the strength and duration of the inflammatory response.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c131 : 1
stoichiometry:c132 : 1
m40*0.1
nodelay
--
0
PMID: 16982211, 12360211 This simultaneous and well-orchestrated activation of NF-kappaB by PAMPs and pro-inflammatory cytokines leads to the production of NF-kappaB-dependent chemokines (e.g. IL-8 and eotaxin), adhesion molecules (e.g. E-selectin and intercellular adhesion molecule 1) and inducible enzymes (e.g. inducible nitric oxide synthase and cyclo-oxygenase-2), all of which contribute to the strength and duration of the inflammatory response.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c134 : 1
stoichiometry:c133 : 1
m108639*0.1
nodelay
--
0
PMID: 16982211, 12360211 This simultaneous and well-orchestrated activation of NF-kappaB by PAMPs and pro-inflammatory cytokines leads to the production of NF-kappaB-dependent chemokines (e.g. IL-8 and eotaxin), adhesion molecules (e.g. E-selectin and intercellular adhesion molecule 1) and inducible enzymes (e.g. inducible nitric oxide synthase and cyclo-oxygenase-2), all of which contribute to the strength and duration of the inflammatory response.
p53
p53
cso30:i:ME_GeneExpression
cso30:i:CC_Nucleoplasm
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c141 : 1
stoichiometry:c139 : 1
m185*0.1
nodelay
--
0
PMID: 16982211, 8557994, 8692885 Because overexpression of A20 was shown to inhibit NF-kappaB activation in response to many stimuli including TNF and IL-1 19 and 20, it was originally suggested that A20 is a feedback inhibitor of NF-kappaB signalling. PMID: 16982211, 8557994, 11463333, 16204640 Interestingly, overexpression of these genes was shown to inhibit TNF-induced and IL-1-induced NF-kappaB activation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c142 : 1
stoichiometry:c140 : 1
m6*0.1
nodelay
--
0
PMID: 16982211, 8557994, 8692885 Because overexpression of A20 was shown to inhibit NF-kappaB activation in response to many stimuli including TNF and IL-1 19 and 20, it was originally suggested that A20 is a feedback inhibitor of NF-kappaB signalling. PMID: 16982211, 8557994, 11463333, 16204640 Interestingly, overexpression of these genes was shown to inhibit TNF-induced and IL-1-induced NF-kappaB activation.
p55
p55
cso30:i:ME_Deubiquitination
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c138 : 1
stoichiometry:c144 : 1
stoichiometry:c145 : 1
m34*m1585*0.1
nodelay
--
0
PMID: 16982211, 15334086, 15258597, 15653317 It was subsequently demonstrated that A20 can disassemble K63 polyubiquitin chains from RIP and TRAF6 in the TNF-receptor-induced and TLR4 [lipopolysaccharide (LPS)]-induced NF-kappaB signalling pathway, respectively.
p56
p56
cso30:i:ME_Deubiquitination
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c137 : 1
stoichiometry:c143 : 1
stoichiometry:c146 : 1
m15*m1585*0.1
nodelay
--
0
PMID: 16982211, 15334086, 15258597, 15653317 It was subsequently demonstrated that A20 can disassemble K63 polyubiquitin chains from RIP and TRAF6 in the TNF-receptor-induced and TLR4 [lipopolysaccharide (LPS)]-induced NF-kappaB signalling pathway, respectively. PMID: 16982211, 15258597, 15653317 The de-ubiquitinating and Ub-conjugating activities of A20 are ordered in two steps: the N-terminal OTU domain of A20 first removes the K63-linked polyubiquitin chains from RIP and inactivates it, and the C-terminal zinc finger domain of A20 catalyses K48 polyubiquitination of RIP, thereby targeting it for proteasomal degradation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c147 : 1
stoichiometry:c148 : 1
m18*0.1
nodelay
--
0
PMID: 16982211, 16684768 Recently, TNF-induced IKKgamma ubiquitination was also reported to be sensitive to A20-mediated de-ubiquitination, indicating that A20 might act at different levels of the NF-kappaB signalling pathway.
p58
p58
cso30:i:ME_Deubiquitination
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c149 : 1
stoichiometry:c151 : 1
stoichiometry:c150 : 1
m47*m1585*0.1
nodelay
--
0
PMID: 16982211, 16684768 Recently, TNF-induced IKKgamma ubiquitination was also reported to be sensitive to A20-mediated de-ubiquitination, indicating that A20 might act at different levels of the NF-kappaB signalling pathway.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c152 : 1
stoichiometry:c153 : 1
stoichiometry:c154 : 1
m183*m48*0.1
nodelay
--
0
PMID: 16982211, 11463333, 12682062 One of them is OTUD7B (also known as Cezanne), which interacts with TRAF6 and inhibits NF-kappaB activation upon overexpression.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c16 : 1
stoichiometry:c17 : 1
m16*0.1
nodelay
--
0
PMID: 16982211 This causes the release of TRAF2 into the cytosol and TRAF2-mediated K63 polyubiqutination of RIP (A2).
p60
p60
cso30:i:ME_Deubiquitination
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c155 : 1
stoichiometry:c157 : 1
stoichiometry:c216 : 1
stoichiometry:c217 : 1
stoichiometry:c156 : 1
m14*m19042*m77*m5930*0.1
nodelay
--
0
PMID: 16982211, 12917690, 12917691, 12917689 Overexpression of CYLD interferes with IKK activation by catalysing the selective cleavage of K63 polyubiquitin chains from TRAF2 and TRAF6, consistent with its inhibitory effect on both TNF-receptor- and TLR?IL-1-receptor-initiated NF-kappaB activation. PMID: 16982211, 11907583, 12411493 For example, the TNF-induced recruitment of TRAF2 to TNF receptor-1 (the main receptor for soluble TNF on most cell types) and TNF receptor-2 (the main receptor for membrane-bound TNF, and primarily expressed on T cells) is followed by TRAF2 ubiquitination by two RING finger Ub ligases: baculoviral IAP repeat-containing 2 (BIRC2; also known as cIAP1) and seven in absentia homolog 2 (SIAH2).
p61
p61
cso30:i:ME_Deubiquitination
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c135 : 1
stoichiometry:c158 : 1
stoichiometry:c136 : 1
m34*m19042*0.1
nodelay
--
0
PMID: 16982211, 12917690, 12917691, 12917689 Overexpression of CYLD interferes with IKK activation by catalysing the selective cleavage of K63 polyubiquitin chains from TRAF2 and TRAF6, consistent with its inhibitory effect on both TNF-receptor- and TLR?IL-1-receptor-initiated NF-kappaB activation. PMID: 16982211, 16543409 Instead, SOCS3 decreased TRAF6 polyubiquitination, thus preventing the association and activation of TAK1.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c160 : 1
stoichiometry:c159 : 1
m40*0.1
nodelay
--
0
PMID: 16982211, 16230348, 15226292 Moreover, endogenous expression of CYLD is upregulated by TNF, IL-1 and TLR2 ligands in an NF-kappaB-dependent way, supporting a negative-feedback role for CYLD in the NF-kappaB pathway.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c161 : 1
stoichiometry:c162 : 1
m204*0.1
nodelay
--
0
PMID: 16982211, 16713561 For example, CYLD was recently shown to de-ubiquitinate B-cell CLL/lymphoma 3 (BCL3), preventing its nuclear translocation.
p64
p64
cso30:i:ME_Deubiquitination
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c163 : 1
stoichiometry:c167 : 1
stoichiometry:c164 : 1
m63*m19042*0.1
nodelay
--
0
PMID: 16982211, 16713561 For example, CYLD was recently shown to de-ubiquitinate B-cell CLL/lymphoma 3 (BCL3), preventing its nuclear translocation.
p65
p65
cso30:i:ME_Translocation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c165 : 1
stoichiometry:c199 : 1
stoichiometry:c166 : 1
m63*0.1
nodelay
--
0
PMID: 16982211, 16713561 For example, CYLD was recently shown to de-ubiquitinate B-cell CLL/lymphoma 3 (BCL3), preventing its nuclear translocation.
p66
p66
cso30:i:ME_Binding
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c168 : 1
stoichiometry:c169 : 1
stoichiometry:c170 : 1
m64276*m180*0.1
nodelay
--
0
PMID: 16982211, 16214042 Recently, ubiquitin specific peptidase 31 (USP31) was identified as another TRAF2 binding DUB that inhibits TNF-induced NF-kappaB activation upon overexpression.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c172 : 1
stoichiometry:c173 : 1
stoichiometry:c174 : 1
m3961*m68*0.1
nodelay
--
0
PMID: 16982211, 15107846 In this context, the RING finger containing Ub ligase Triad3A was shown to bind and induce the ubiquitination and degradation of TLR4 and TLR9, but not TLR2.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c175 : 1
stoichiometry:c176 : 1
stoichiometry:c177 : 1
m68*m19828*0.1
nodelay
--
0
PMID: 16982211, 15107846 In this context, the RING finger containing Ub ligase Triad3A was shown to bind and induce the ubiquitination and degradation of TLR4 and TLR9, but not TLR2.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c178 : 1
stoichiometry:c179 : 1
m67*0.1
nodelay
--
0
PMID: 16982211, 15107846 In this context, the RING finger containing Ub ligase Triad3A was shown to bind and induce the ubiquitination and degradation of TLR4 and TLR9, but not TLR2.
p7
p7
cso30:i:ME_Binding
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c18 : 1
stoichiometry:c19 : 1
stoichiometry:c20 : 1
stoichiometry:c27 : 1
stoichiometry:c21 : 1
m6433*m19389*m1637*m15*0.1
nodelay
--
0
PMID: 16982211 K63 polyubiquitinated RIP is recognized by the TAK1-binding proteins TAB2 and TAB3 (blue), as well as by IkappaB kinase gamma (IKKgamma; light green).
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c180 : 1
stoichiometry:c181 : 1
m66*0.1
nodelay
--
0
PMID: 16982211, 15107846 In this context, the RING finger containing Ub ligase Triad3A was shown to bind and induce the ubiquitination and degradation of TLR4 and TLR9, but not TLR2.
p71
p71
cso30:i:ME_ProteasomeDegradation
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c182 : 1
stoichiometry:c185 : 1
m70*0.1
nodelay
--
0
PMID: 16982211, 15107846 In this context, the RING finger containing Ub ligase Triad3A was shown to bind and induce the ubiquitination and degradation of TLR4 and TLR9, but not TLR2.
p72
p72
cso30:i:ME_ProteasomeDegradation
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c183 : 1
stoichiometry:c184 : 1
m69*0.1
nodelay
--
0
PMID: 16982211, 15107846 In this context, the RING finger containing Ub ligase Triad3A was shown to bind and induce the ubiquitination and degradation of TLR4 and TLR9, but not TLR2.
p73
p73
cso30:i:ME_Binding
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c186 : 1
stoichiometry:c188 : 1
stoichiometry:c189 : 1
stoichiometry:c190 : 1
stoichiometry:c191 : 1
stoichiometry:c195 : 1
stoichiometry:c187 : 1
m71*m72*m3559*m3558*m3551*m72721*0.1
nodelay
--
0
PMID: 16982211, 15899873 In addition, TNF-receptor-2 plasma-membrane levels are regulated by TNF-induced K48 polyubiquitination mediated by Ankyrin repeat and SOCS box-containing 3 (ASB3), which confers its Ub-ligase activity via an interaction with elongin B?elongin C and the recruitment of the Ub-transferase system composed of cullin-2, Rbx2 and E2. PMID: 16982211 SOCS proteins are characterized by a C-terminal SOCS-box domain that allows the binding of the elongin-B?elongin-C complex to form a functional E3 Ub ligase.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c196 : 1
stoichiometry:c197 : 1
stoichiometry:c105 : 1
m6*m1836*0.1
nodelay
--
0
PMID: 16982211, 11907583, 12411493 For example, the TNF-induced recruitment of TRAF2 to TNF receptor-1 (the main receptor for soluble TNF on most cell types) and TNF receptor-2 (the main receptor for membrane-bound TNF, and primarily expressed on T cells) is followed by TRAF2 ubiquitination by two RING finger Ub ligases: baculoviral IAP repeat-containing 2 (BIRC2; also known as cIAP1) and seven in absentia homolog 2 (SIAH2).
p75
p75
cso30:i:ME_Binding
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c198 : 1
stoichiometry:c51 : 1
stoichiometry:c200 : 1
m1836*m175*0.1
nodelay
--
0
PMID: 16982211, 11907583, 12411493 For example, the TNF-induced recruitment of TRAF2 to TNF receptor-1 (the main receptor for soluble TNF on most cell types) and TNF receptor-2 (the main receptor for membrane-bound TNF, and primarily expressed on T cells) is followed by TRAF2 ubiquitination by two RING finger Ub ligases: baculoviral IAP repeat-containing 2 (BIRC2; also known as cIAP1) and seven in absentia homolog 2 (SIAH2).
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c192 : 1
stoichiometry:c194 : 1
stoichiometry:c193 : 1
m1836*m74*0.1
nodelay
--
0
PMID: 16982211, 15899873 In addition, TNF-receptor-2 plasma-membrane levels are regulated by TNF-induced K48 polyubiquitination mediated by Ankyrin repeat and SOCS box-containing 3 (ASB3), which confers its Ub-ligase activity via an interaction with elongin B?elongin C and the recruitment of the Ub-transferase system composed of cullin-2, Rbx2 and E2.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c201 : 1
stoichiometry:c202 : 1
stoichiometry:c203 : 1
m75*m180*0.1
nodelay
--
0
PMID: 16982211, 11907583, 12411493 For example, the TNF-induced recruitment of TRAF2 to TNF receptor-1 (the main receptor for soluble TNF on most cell types) and TNF receptor-2 (the main receptor for membrane-bound TNF, and primarily expressed on T cells) is followed by TRAF2 ubiquitination by two RING finger Ub ligases: baculoviral IAP repeat-containing 2 (BIRC2; also known as cIAP1) and seven in absentia homolog 2 (SIAH2).
p78
p78
cso30:i:ME_Ubiquitination
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c208 : 1
stoichiometry:c209 : 1
stoichiometry:c212 : 1
stoichiometry:c205 : 1
m79*m5930*m86*0.1
nodelay
--
0
PMID: 16982211, 11907583, 15861135 Binding of BIRC2 to TRAF2 at TNF receptor-2 induces the translocation of the TRAF2?BIRC2 complex to an endoplasmic-reticulum-associated compartment, where BIRC2 ubiquitinates TRAF2, thereby triggering its proteasomal degradation and the subsequent cessation of TRAF2-mediated signalling. PMID: 16982211, 11907583, 12411493 For example, the TNF-induced recruitment of TRAF2 to TNF receptor-1 (the main receptor for soluble TNF on most cell types) and TNF receptor-2 (the main receptor for membrane-bound TNF, and primarily expressed on T cells) is followed by TRAF2 ubiquitination by two RING finger Ub ligases: baculoviral IAP repeat-containing 2 (BIRC2; also known as cIAP1) and seven in absentia homolog 2 (SIAH2).
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c204 : 1
stoichiometry:c206 : 1
stoichiometry:c207 : 1
m76*m77*0.1
nodelay
--
0
PMID: 16982211, 11907583, 15861135 Binding of BIRC2 to TRAF2 at TNF receptor-2 induces the translocation of the TRAF2?BIRC2 complex to an endoplasmic-reticulum-associated compartment, where BIRC2 ubiquitinates TRAF2, thereby triggering its proteasomal degradation and the subsequent cessation of TRAF2-mediated signalling.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c22 : 1
stoichiometry:c23 : 1
stoichiometry:c24 : 1
m1573*m17*0.1
nodelay
--
0
PMID: 16982211 This brings the kinase TAK1 (light grey) in close proximity to the IKK complex, allowing it to phosphorylate the catalytic IKKalpha and IKKbeta subunits (pink; A3).
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c210 : 1
stoichiometry:c211 : 1
m79*0.1
nodelay
--
0
PMID: 16982211, 11907583, 15861135 Binding of BIRC2 to TRAF2 at TNF receptor-2 induces the translocation of the TRAF2?BIRC2 complex to an endoplasmic-reticulum-associated compartment, where BIRC2 ubiquitinates TRAF2, thereby triggering its proteasomal degradation and the subsequent cessation of TRAF2-mediated signalling.
p81
p81
cso30:i:ME_ProteasomeDegradation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c213 : 1
stoichiometry:c218 : 1
stoichiometry:c214 : 1
stoichiometry:c215 : 1
m78*m5930*0.1
nodelay
--
0
PMID: 16982211, 11907583, 15861135 Binding of BIRC2 to TRAF2 at TNF receptor-2 induces the translocation of the TRAF2?BIRC2 complex to an endoplasmic-reticulum-associated compartment, where BIRC2 ubiquitinates TRAF2, thereby triggering its proteasomal degradation and the subsequent cessation of TRAF2-mediated signalling. PMID: 16982211, 12411493 Similarly, the triggering of TNF receptor-1 induces proteasomal degradation of TRAF2 upon overexpression of the E3 Ub ligase SIAH2.
p82
p82
cso30:i:ME_ProteasomeDegradation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c219 : 1
stoichiometry:c220 : 1
m16*0.1
nodelay
--
0
PMID: 16982211, 15258597, 15653317 The de-ubiquitinating and Ub-conjugating activities of A20 are ordered in two steps: the N-terminal OTU domain of A20 first removes the K63-linked polyubiquitin chains from RIP and inactivates it, and the C-terminal zinc finger domain of A20 catalyses K48 polyubiquitination of RIP, thereby targeting it for proteasomal degradation.
PMID: 16982211, 8557994, 11463333, 16204640 Interestingly, overexpression of these genes was shown to inhibit TNF-induced and IL-1-induced NF-kappaB activation.
PMID: 16982211, 8557994, 11463333, 16204640 Interestingly, overexpression of these genes was shown to inhibit TNF-induced and IL-1-induced NF-kappaB activation.
PMID: 16982211, 8557994, 11463333, 16204640 Interestingly, overexpression of these genes was shown to inhibit TNF-induced and IL-1-induced NF-kappaB activation.
PMID: 16982211, 8557994, 11463333, 16204640 Interestingly, overexpression of these genes was shown to inhibit TNF-induced and IL-1-induced NF-kappaB activation.
p87
p87
cso30:i:ME_Ubiquitination
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c230 : 1
stoichiometry:c231 : 1
stoichiometry:c232 : 1
m1906*m93*0.1
nodelay
--
0
PMID: 16982211, 16415872 Recently, it was observed that the TLR2 and TLR4 adaptor protein MyD88 adaptor-like (MAL, also known as TIRAP) is phosphorylated and ubiquitinated in a SOCS1-dependent manner upon TLR stimulation, thereby targeting MAL for proteasomal degradation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c233 : 1
stoichiometry:c234 : 1
m25*0.1
nodelay
--
0
PMID: 16982211, 16415872 Recently, it was observed that the TLR2 and TLR4 adaptor protein MyD88 adaptor-like (MAL, also known as TIRAP) is phosphorylated and ubiquitinated in a SOCS1-dependent manner upon TLR stimulation, thereby targeting MAL for proteasomal degradation.
p89
p89
cso30:i:ME_ProteasomeDegradation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c235 : 1
stoichiometry:c238 : 1
stoichiometry:c236 : 1
stoichiometry:c237 : 1
m92*m1906*0.1
nodelay
--
0
PMID: 16982211, 16415872 Recently, it was observed that the TLR2 and TLR4 adaptor protein MyD88 adaptor-like (MAL, also known as TIRAP) is phosphorylated and ubiquitinated in a SOCS1-dependent manner upon TLR stimulation, thereby targeting MAL for proteasomal degradation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c25 : 1
stoichiometry:c26 : 1
m20*0.1
nodelay
--
0
PMID: 16982211 This brings the kinase TAK1 (light grey) in close proximity to the IKK complex, allowing it to phosphorylate the catalytic IKKalpha and IKKbeta subunits (pink; A3).
p90
p90
cso30:i:ME_Ubiquitination
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c239 : 1
stoichiometry:c243 : 1
stoichiometry:c240 : 1
m1617*m1906*0.1
nodelay
--
0
PMID: 16982211, 12433373, 14690596 Indeed, an interaction of SOCS1 with IRAK1 as well as SOCS1-mediated ubiquitination and subsequent degradation of the p65 NF-¦ÊB subunit suggest a more downstream inhibitory effect of SOCS1 in TLR signalling pathways.
p91
p91
cso30:i:ME_UnknownDegradation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c241 : 1
stoichiometry:c244 : 1
stoichiometry:c242 : 1
m94*m1906*0.1
nodelay
--
0
PMID: 16982211, 12433373, 14690596 Indeed, an interaction of SOCS1 with IRAK1 as well as SOCS1-mediated ubiquitination and subsequent degradation of the p65 NF-¦ÊB subunit suggest a more downstream inhibitory effect of SOCS1 in TLR signalling pathways.
p92
p92
cso30:i:ME_Binding
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c245 : 1
stoichiometry:c246 : 1
stoichiometry:c247 : 1
m184*m1906*0.1
nodelay
--
0
PMID: 16982211, 12433373, 14690596 Indeed, an interaction of SOCS1 with IRAK1 as well as SOCS1-mediated ubiquitination and subsequent degradation of the p65 NF-¦ÊB subunit suggest a more downstream inhibitory effect of SOCS1 in TLR signalling pathways.
p93
p93
cso30:i:ME_Binding
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c248 : 1
stoichiometry:c249 : 1
stoichiometry:c250 : 1
stoichiometry:c251 : 1
m2005*m183*m1573*0.1
nodelay
--
0
PMID: 16982211, 16543409 This is further supported by the finding that overexpression of SOCS3 inhibits IL-1-induced NF-kappaB activation and co-immunoprecipitates with the TRAF6?TAK1 complex.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c253 : 1
stoichiometry:c256 : 1
stoichiometry:c254 : 1
m37*0.1
nodelay
--
0
PMID: 16982211, 16543409 This is further supported by the finding that overexpression of SOCS3 inhibits IL-1-induced NF-kappaB activation and co-immunoprecipitates with the TRAF6?TAK1 complex. PMID: 16982211, 16543409 Instead, SOCS3 decreased TRAF6 polyubiquitination, thus preventing the association and activation of TAK1.
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--